Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.Potential first-in-class oral prolonged-release formulation of ketamine, KET01,
Appointment accelerates Company's development roadmap in targeted therapies for neuropsychiatric disorders The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry
In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects The Company has also established